### **Overview** Morepen Laboratories Ltd. is a rapidly expanding Indian pharmaceutical and healthcare company with vertically integrated operations across **Active Pharmaceutical Ingredients (APIs)**, **Formulations**, **Over-the-Counter (OTC) products**, and **Home Diagnostic Medical Devices**. The company is positioned as a global leader in key APIs and a dominant player in India’s home diagnostics market. With a strategic focus on high-value molecules, backward integration, innovation, and consumer-centric branding under the **Dr. Morepen** umbrella, Morepen is undergoing a transformation dubbed “**Morepen 2.0**” — supported by capital infusion, technology upgrades, and business model refinement. --- ### **Core Business Segments & Market Positioning** #### **1. Active Pharmaceutical Ingredients (APIs)** - **Global Leadership**: - **Loratadine**: Largest global supplier by volume (35% market share in FY24), with over 65% export market share from India. - **Montelukast Sodium**: World’s largest manufacturer (44% market share in FY24), produced at USFDA- and PMDA-approved facilities in Masulkhana and Baddi, Himachal Pradesh. - **Desloratadine**: Leading global supplier (26% market share in FY24). - **Fexofenadine**: 3rd largest global manufacturer (16% market share), 3rd largest exporter from India. - **Atorvastatin & Rosuvastatin**: 4th largest global manufacturer by volume (11% and 9% share respectively). - **Regulatory Strength**: - 363 global **Drug Master Files (DMFs)** filed, including 29 in the US and 13 CEPs in Europe (all granted). - USFDA re-approvals (2022) and Japan PMDA approval (2023) for key APIs. - NMPA China approval for Loratadine exports (Apr 2025), marking entry into the critical Chinese market. - **R&D Pipeline**: - Focus on **complex generics** ahead of patent expiries: Sitagliptin, Empagliflozin, Sotagliflozin, Elagolix. - Development of **NASH drug Resmetirom**, **Finerenone** (heart failure/CKD), **Cariprazine HCl** (antipsychotic), **Bempedoic Acid**, and **Ozanimod** (MS). - Anti-cancer pipeline: Enzalutamide, Nintedanib, and top-100 oncology synthetic molecules. - **Intellectual Property**: - 55 granted patents (39 in India, 16 overseas). - 167 process/polymorph patents filed, including novel forms of Rosuvastatin, Sitagliptin, and Vortioxetine. - Efficient, green manufacturing processes developed to reduce waste and improve sustainability. #### **2. Medical Devices & Diagnostics** - **Market Leadership**: - **#1 in India** for **blood glucose meters** (15 million units installed as of Aug 2025) and **blood pressure (BP) monitors**. - Over **1.5 billion test strips** sold to date; ~78% of device revenue from glucometers, ~19% from BP monitors. - Fully backward-integrated supply chain with in-house manufacturing since 2015 (bare PCB level). - **Growth Strategy**: - "**Printer cartridge model**": low-margin meter sales drive high-margin recurring strip sales. - Strip-to-meter sales ratio improved from 150 to **165–167**, indicating higher user engagement. - Annual glucometer sales revenue grew from ₹327 crore (FY24) to ₹443 crore (FY25), **+35% YoY**. - Q3 FY25: **15% YoY revenue growth (₹123 cr vs ₹107 cr)**; 9-month growth: ₹394 cr (+11%). - **Capacity Expansion**: - Plans to double annual production capacity: **2.5M → 5M glucometers**, **500M → 700M strips/year**. - Production increased by 37% in 9M FY25 due to new lines; demand fully met. - **Product Diversification**: - Expansion into **orthopedic products** and **infectious disease diagnostics** (lateral flow tests, blood grouping reagents). - ISO 13485 certified manufacturing; all devices made in India. - In-house pregnancy test kit production launched, replacing imports. #### **3. Formulations & OTC Business** - **Branded OTC Portfolio**: - Dr. Morepen Limited (established 2001) handles OTC business with strong brands: **Burnol**, **Lemolate**, **Isabgol**, **Pain-X**, **Fiber-X**. - Recognized in **Limca Book of Records** for redefining OTC as FMCG. - **Growth Initiatives**: - Launched **'LightLife'**, a 360-degree weight management program with Slimbiome® (UK) and Intelicaps Probiotics (Belgium) at ₹599. - Intebact: Proprietary probiotic with Intelicaps® tech for targeted colon delivery (1,000x higher concentration than conventional). - Distribution expanded via **Chemist Franchise Associates (CFA)** model. - Partnerships with **Indian Army** (Eastern & Northern Command), **Apollo Pharmacy**, **Sevio Pharma**. - **Digital Expansion**: - Online OTC sales now **22% of segment revenue** (up from 16% in FY23), with 23% YoY growth. - Direct-to-consumer presence via **www.drmorepen.com** (50+ online-only products). - Surge in online lifestyle products: **+243% YoY** (multivitamins, sleep aids, wellness). --- ### **Key Strategic Developments (2024–2025)** #### **Capital Raise & “Morepen 2.0”** - Raised capital via **QIP led by Motilal Oswal** (Aug 2024), launching **“Morepen 2.0”**. - Funds allocated to: - Expand capacity in **glucometers, BP monitors, and APIs**. - Enhance R&D, brand building, and backward integration. - Debt-free balance sheet; future capex funded via internal accruals (₹50–75 crore for devices, ₹3–4 crore for APIs). - Aims to improve **EBITDA margins by 3–4%**, achieve **15–20% revenue CAGR**, and **25–27% CAGR in medical devices**. #### **R&D & Innovation** - Focus on **high-value, complex generics** and **regulated markets**. - Recent completions: - **Sitagliptin HCl**, **Finerenone**, **Cariprazine HCl**, **Bempedoic Acid**, **Rupatadine Fumarate**, **Resmetirom Form I**. - Cost-effective synthesis for **USP/EP-grade Rosuvastatin calcium**. - CDSCO filing for Resmetirom dosage form in India. #### **Digital & Ecosystem Play** - **Dr. Morepen Sync App** ("Health in Your Hands") launched to monitor blood glucose, BP, and weight. - Supports long-term engagement with medical device ecosystem. - Branded campaign with partnerships (e.g., **KBC desktop branding**). - App strengthens recurring revenue model but not yet tied to direct revenue. #### **Manufacturing & Supply Chain** - 3 integrated plants in **Himachal Pradesh** (Baddi, Parwanoo, Masulkhana). - **ISO 13485 certified** for medical devices; USFDA, EU GMP, WHO GMP, PMDA compliant. - 5,100+ distributors; 328,000 retail touchpoints; 580+ sales force. - Fully self-reliant in glucometer and strip production (since 2015); no import dependency. --- ### **Financial & Operational Highlights** - **API Revenue Growth**: +10% YoY despite pricing pressures, driven by volume and lower raw material costs. - **Medical Devices**: ~**30% of total revenue**, growing faster than other segments; projected to lead future growth. - **Formulations Revenue (Aug 2025)**: ₹13,868.86 lakhs (+3.9% YoY), post restructuring to subsidiary Dr. Morepen Limited. - **Margin Strategy**: - Shifting from low-margin third-party manufacturing to **high-margin direct trade and institutional sales**. - API margins under pressure due to maturity of 6–7 legacy products; recovery expected via **new launches post-patent expiry** (e.g., Sotagliflozin, Empagliflozin). - **Asset Efficiency**: - High asset turnover (5–6x), expected to remain at **3–4x** for new investments. - Legacy infrastructure generating ₹1,500 crore revenue on ₹200–250 crore asset base.